Real World Study of Lapatinib Among Metastatic Breast Cancer Patients

Fudan University

Status: Completed

Conditions: Breast Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT03894410

YOUNGBC-6

Details and patient eligibility

About

A multicenter, retrospective, real world study of Lapatinib among Metastatic Breast Cancer (MBC) Patients in Clinical Practice.

Full description

This study collected patients used Lapatinib-base therapy among MBC, and tried to figure out if there was difference between single anti-Her2 treatment and dual anti-Her2 treatment. Furthermore, this study investigated the treatment after Lapatinib.

Enrollment: 242 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who were treated with Lapatinib between June 2014 to June 2018.
• Patients experienced progression on prior trastuzumab-containing regimens and a taxane.
• Complete medical history was available.

Exclusion criteria

• Medical history was incomplete.

Trial design

242 participants in 4 patient groups

Continuing Lapatinib

Description:

Patients continued using treatment containing Lapatinib after progression on Lapatinib.

Change HER-2 treatment

Description:

Patients changed to another HER-2 targeted treatment after progression on Lapatinib (ado-trastuzumab emtansine, trastuzumab, etc.).

Lapatinib plus capetabine

Description:

Patients used lapatinib plus capetabine.

Lapatinib plus Trastuzumab and one chemotherapy

Description:

Patients used lapatinib plus trastuzumab and one chemo regimen.